Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…Abstract Number: 1702 • 2017 ACR/ARHP Annual Meeting
Disease Progression in Systemic Sclerosis Patients with Concomittant or Isolated Interstitial Lung Disease and Pulmonary Arterial Hypertension in the Scleroderma Cohort Singapore
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are leading causes of mortality in patients with systemic sclerosis (SSc). We aimed to determine…Abstract Number: 2189 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome Influences the Radiographic Progression of Knee Osteoarthritis and Condition the Risk of Erosive Hand OA
Background/Purpose: The contribution of metabolic factors in the development of OA has not been fully elucidated. The aim of this work is to analyze the…Abstract Number: 2308 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Comorbidities in Pediatric Psoriasis and Juvenile Psoriatic Arthritis
Background/Purpose: Adult-onset psoriasis (PsO) and psoriatic arthritis (PsA) have been associated with increased rates of diabetes, obesity, and hypertension. We sought to evaluate the prevalence…Abstract Number: 973 • 2016 ACR/ARHP Annual Meeting
Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients (pts) with Systemic Sclerosis (SSc). The World Health Organization (WHO) classifies PH into…Abstract Number: 1477 • 2016 ACR/ARHP Annual Meeting
Exploring the Inadequate Cardiovascular Disease Prevention in Inflammatory Joint Diseases: Results from a Nationwide Norwegian Project
Background/Purpose: Antihypertensives (antiHT) and lipid lowering therapies (LLT) prevent cardiovascular disease (CVD) effectively. It has been reported that patients with rheumatoid arthritis (RA) receive suboptimal…Abstract Number: 1481 • 2016 ACR/ARHP Annual Meeting
Success Rate of Blood Pressure Goal Achievement in Patients with Inflammatory Joint Diseases
Background/Purpose: The excess risk of cardiovascular disease (CVD) in patients with inflammatory joint diseases (IJD) is attributable to several risk factors, including a high prevalence…Abstract Number: 2051 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Cardiovascular Disease Predate the Onset of Symptoms of Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular (CV) comorbidity compared with the general population. Contradictory results concerning CV disease…Abstract Number: 2161 • 2016 ACR/ARHP Annual Meeting
Association Between Inflammation and Systolic Blood Pressure at Normal and High C-Reactive Protein Levels
Background/Purpose: While inflammation is linked with higher blood pressure (BP) in the general population, few studies have examined this relationship in patients with elevated levels…Abstract Number: 2171 • 2016 ACR/ARHP Annual Meeting
Increased Rates of Hypertension in Patients with Psoriatic Arthritis Compared to Psoriasis Alone: Results from the UK Biobank
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with the presence of psoriasis. Both conditions are influenced by lifestyle factors such as alcohol…Abstract Number: 2287 • 2016 ACR/ARHP Annual Meeting
Serum Urate and Its Association with Endothelial Dysfunction in Young Adults
Background/Purpose: Both serum urate (sUA) and endothelial dysfunction have been associated with hypertension and cardiovascular disease. Increasing sUA level has been associated with endothelial dysfunction…Abstract Number: 2294 • 2016 ACR/ARHP Annual Meeting
Uric Acid Production and Blood Pressure: The Role of Uric Acid Concentration As Well As Uric Acid Production
Background/Purpose: Blood pressure and hypertension are associated with uric acid, the end product of purine catabolism, but the underlying mechanism remainds unclear. During the final…Abstract Number: 2357 • 2016 ACR/ARHP Annual Meeting
Topical Application of Aceclofenac Might NOT Produce a Significant Increase of Blood Pressure in Osteoarthritic Patients – a Continuous Automated Blood Pressure Monitor Study
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in Osteoarthritic patients for their anti-inflammatory and pain-killer proprieties. Various reports suggest an increase in blood pressure…Abstract Number: 22 • 2016 ACR/ARHP Annual Meeting
Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease(NAFLD) Among Patients with Rheumatoid Arthritis
Background/Purpose: NAFLD is a leading cause of chronic liver disorders, unrelated to significant alcohol use. RA and NAFLD have shared risk factors such as age,…Abstract Number: 23 • 2016 ACR/ARHP Annual Meeting
Incidence of Non Alcoholic Fatty Liver Disease By Key Risk Factors Among Patients with Rheumatoid Arthritis
Background/Purpose: The prevalence and characteristics of patients with nonalcoholic fatty liver disease (NAFLD) have not been well characterized in the RA population. The purpose of…